Efficacy of Injection Immunotherapy with Ragweed and Birch Pollen in Elderly PatientsAsero R.
Ambulatorio di Allergologia, Clinica San Carlo, Paderno Dugnano, Italia
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Background: The role of specific immunotherapy (SIT) in elderly allergic patients is still debated. Objective: The aim of this study was to assess whether SIT is associated with a better control of symptoms and a better quality of life also in older allergic patients. Methods: The effect of injection SIT was assessed in 39 patients [age >54 years, median 59; 29 patients (74%) with asthma, otherwise healthy] monosensitized to birch (n = 20) and ragweed (n = 19). Thirty-three younger subjects [age <50 years, median 35; 26 patients (79%) with asthma, otherwise healthy] monosensitized to birch (n = 10) and ragweed (n = 23), and 37 subjects >54 years old (25 males/12 females; age 55–79 years, median 59 years) monosensitized to birch (n = 18) and ragweed (n = 19) who refused to undergo SIT were enrolled as positive and negative controls, respectively. All groups had a disease duration <10 years; the disease was inadequately controlled with standard drug therapies in all cases. SIT was carried out using the same extracts and was administered using a perennial schedule both in patients and controls. Seasonal therapies were the same in all groups and were not changed after SIT was started. After 1–5 years of SIT, patients and controls were asked to quantify symptom reduction on a visual analogue scale: reductions >50% were considered significant. Moreover, the use of cetirizine and/or salbutamol as an adjunct to standard therapies during the last pollen season was assessed as an objective measure of SIT outcome. Results: 37/39 (95%) patients versus 32/33 (97%) controls submitted to SIT reported a symptom reduction >50% after 1–5 years of SIT (nonsignificant). The median clinical efficacy of SIT was 80% in both groups (nonsignificant). 27/37 controls not submitted to SIT did not report any change in symptom severity at the follow-up visits, whereas 10/37 reported a more severe disease (4 subjects reported the appearance of seasonal asthma) (p < 0.001 vs. patients submitted to SIT). Patients used less frequently cetirizine (p < 0.001) and/or salbutamol (p < 0.05) than controls not submitted to SIT. Conclusion: Injection SIT can be considered an effective therapeutic option in otherwise healthy elderly patients with a short disease duration whose symptoms cannot be adequately controlled by drug therapies alone.
© 2004 S. Karger AG, Basel
Malling HJ, Weeke B (eds): EAACI Position paper: Immunotherapy. Allergy 1993;48(suppl 14):9–34.
Bousquet J, Lockey RF, Malling HJ: WHO position paper. Allergen immunotherapy: Therapeutical vaccines for allergic disease. Allergy 1998;53(suppl 44):1–42.
- Jacobsen L, Nuchel-Petersen B, Wihl JA, Lowenstein H, Ipsen H: Immunotherapy with partially purified and standardized tree pollen extract. IV. Results from long-term (6-year) follow-up. Allergy 1997;52:914–920.
- Durham SR, Walker SM, Varga EM, et al: Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999;341:468–475.
- Bousquet J, Hejjaoui A, Clauzel AM, Guerin B, et al: Specific immunotherapy with a standardized Dermatophagoides pteronyssinus extract. II. Prediction of efficacy of immunotherapy. J Allergy Clin Immunol 1988;82:971–977.
- Bousquet J, Hejaoui A, Michel F-B: Specific immunotherapy in asthma. J Allergy Clin Immunol 1990;86:292–305.
Dal Bo S, Dal Bo GA: La pollinosi da betulla e da Betulaceae. Giorn It Allergol Immunol Clin 1991;1:475–478.
- D’Amato G, Spieksma FT, Liccardi G, Jager S, et al: Pollen-related allergy in Europe. Allergy 1998;53:567–578.
Piazza G, Cassani L, Sesia O, Corti M, Della Torre F: Ragweed evidence in a North Milan hill area (abstract). International Symposium. Pollinosis in the Mediterranean Area. Naples, March 1989, p 197.
Bottero P, Venegoni E, Riccio G, et al: Pollinosi da Ambrosia artemisiifolia in provincia di Milano. Folia Allergol Immunol Clin 1990;37:99–103.
- Asero R: Birch and ragweed pollinosis north of Milan: A model to investigate the effects of exposure to ‘new’ airborne allergens. Allergy 2002;57:1063–1066.
- Juniper EF, Guyatt GH: Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy 1991;21:77–83.
- Eidelman F, Darzentas N: Efficacy of allergy immunotherapy in the elderly (abstract). J Allergy Clin Immunol 2000;105:S313.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.